Alume Biosciences is a clinical-stage biotechnology company in La Jolla, California, developing nerve-targeted fluorescent agents for precision surgery. Its lead candidate, bevonescein (ALM-488) — a peptide-dye conjugate co-invented by the late Nobel Laureate Dr. Roger Tsien and surgeon Dr. Quyen Nguyen — is administered intravenously roughly an hour before an operation so surgeons can see nerves illuminated in the surgical field and avoid inadvertent nerve injury. The compound has FDA Fast Track designation, is in Phase 3 pivotal trials in head-and-neck surgery, and the company has stated it plans a New Drug Application submission in 2026. Alume is a drug developer, not a software vendor: it publishes no developer program, API, SDK or machine-readable specification.
Alume Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Pharmaceuticals, and Clinical Trials.
Alume Biosciences’ developer surface includes engineering blog and 8 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: alume-biosciences
name: Alume Biosciences
description: 'Alume Biosciences is a clinical-stage biotechnology company in La Jolla, California, developing nerve-targeted
fluorescent agents for precision surgery. Its lead candidate, bevonescein (ALM-488) — a peptide-dye conjugate co-invented
by the late Nobel Laureate Dr. Roger Tsien and surgeon Dr. Quyen Nguyen — is administered intravenously roughly an hour
before an operation so surgeons can see nerves illuminated in the surgical field and avoid inadvertent nerve injury. The
compound has FDA Fast Track designation, is in Phase 3 pivotal trials in head-and-neck surgery, and the company has stated
it plans a New Drug Application submission in 2026. Alume is a drug developer, not a software vendor: it publishes no developer
program, API, SDK or machine-readable specification.'
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://alumebiosciences.com/wp-content/uploads/2019/08/apple-icon-180x180.png
url: https://raw.githubusercontent.com/api-evangelist/alume-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Clinical Trials
- Surgery
- Medical Imaging
- Health
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://alumebiosciences.com/
- type: About
url: https://alumebiosciences.com/about-us/
- type: Blog
url: https://alumebiosciences.com/news/
- type: Contact
url: https://alumebiosciences.com/contact/
- type: Careers
url: https://alumebiosciences.com/careers/
- type: Twitter
url: https://twitter.com/alumebioscience
- type: Instagram
url: https://instagram.com/alumebiosciences
- type: DomainSecurity
url: security/alume-biosciences-domain-security.yml
- type: LLMsTxt
url: llms/alume-biosciences-llms.txt
x-enrichment:
date: '2026-08-06'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Alume Biosciences is a clinical-stage drug developer whose entire web presence is a five-page WordPress marketing
site (about, news, careers, contact) with no developer, API or documentation section anywhere in its sitemap; the only
machine-readable endpoint on the host is the default WordPress /wp-json/ CMS route index, which is site infrastructure
and not a published API product.
evidence:
- url: https://alumebiosciences.com/openapi.json
status: 404
- url: https://alumebiosciences.com/.well-known/agent-card.json
status: 404
- url: https://alumebiosciences.com/llms.txt
status: 404
- url: https://alumebiosciences.com/wp-sitemap-posts-page-1.xml
status: 200
- url: https://github.com/alumebio
status: 404
checked: '2026-08-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →